- Home
- MODD vs ATRA Comparison
MODD vs ATRA Comparison
Compare MODD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- ATRA
- Stock Information
- Founded
- MODD 1998
- ATRA 2012
- Country
- MODD United States
- ATRA United States
- Employees
- MODD N/A
- ATRA N/A
- Industry
- MODD Industrial Specialties
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MODD Health Care
- ATRA Health Care
- Exchange
- MODD Nasdaq
- ATRA Nasdaq
- Market Cap
- MODD 35.5M
- ATRA 32.4M
- IPO Year
- MODD N/A
- ATRA 2014
- Fundamental
- Price
- MODD $0.89
- ATRA $6.17
- Analyst Decision
- MODD
- ATRA Buy
- Analyst Count
- MODD 0
- ATRA 5
- Target Price
- MODD N/A
- ATRA $17.75
- AVG Volume (30 Days)
- MODD 155.4K
- ATRA 47.4K
- Earning Date
- MODD 02-13-2025
- ATRA 05-08-2025
- Dividend Yield
- MODD N/A
- ATRA N/A
- EPS Growth
- MODD N/A
- ATRA N/A
- EPS
- MODD N/A
- ATRA N/A
- Revenue
- MODD N/A
- ATRA $128,940,000.00
- Revenue This Year
- MODD N/A
- ATRA N/A
- Revenue Next Year
- MODD N/A
- ATRA N/A
- P/E Ratio
- MODD N/A
- ATRA N/A
- Revenue Growth
- MODD N/A
- ATRA 1404.02
- 52 Week Low
- MODD $0.68
- ATRA $5.01
- 52 Week High
- MODD $2.65
- ATRA $19.00
- Technical
- Relative Strength Index (RSI)
- MODD 43.99
- ATRA 47.91
- Support Level
- MODD $0.79
- ATRA $5.16
- Resistance Level
- MODD $0.95
- ATRA $6.11
- Average True Range (ATR)
- MODD 0.10
- ATRA 0.61
- MACD
- MODD -0.01
- ATRA 0.08
- Stochastic Oscillator
- MODD 28.42
- ATRA 78.98
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).